For elderly or comorbid patients, the high toxicity of powerful, time-limited combination therapies can outweigh their efficacy. A less harsh, continuous monotherapy is often preferable as it better preserves quality of life, even if it doesn't offer a treatment-free interval or a theoretical "100% life back."

Medical progress isn't just about new therapies; it's also about de-escalation, such as reducing the number of radiotherapy sessions. This type of innovation significantly improves a patient's quality of life by minimizing the exhaustive and disruptive time spent in treatment, a benefit patients value highly.

A patient's disease stage fundamentally changes their risk calculus. In the metastatic setting, where the primary goal is survival, patients willingly endure significant toxicity as long as their cancer is controlled. In the adjuvant (curative) setting, the long-term impact of that same toxicity becomes a more critical factor.

For older, transplant-ineligible patients, well-tolerated, long-term regimens from trials like CFIUS shift the treatment goal. Success is defined as managing myeloma so effectively that patients are more likely to die of other age-related causes, effectively outliving their cancer.

The ASH-AYA-ALL guidelines explicitly state that a major goal is not only to improve survival but also to enhance quality of life during and after treatment. This includes a focus on avoiding long-term toxicities and preserving fertility, signaling a formal shift towards prioritizing the patient's long-term, healthy, and productive future beyond just curing the disease.

The primary goal in Chronic Myeloid Leukemia (CML) has evolved from survival to tolerability and treatment-free remission. These goals are not uniform; younger patients prioritize stopping treatment to start families, while long-term patients increasingly value better tolerability over marginal efficacy gains.

The classic study suggesting >90% adherence is necessary for CML response is outdated. Modern practice shows that controlled dose reductions to improve tolerability can actually lead to better overall outcomes, challenging the idea that perfect adherence to the initial prescribed dose is paramount.

Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.

The LIDERA trial showed that while jiridestrant and standard therapies had similar adverse event profiles, patients on jiridestrant had significantly lower discontinuation rates. This highlights that a patient's subjective experience of tolerability is a more critical factor for long-term adherence than a simple list of side effects.